InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Discover the full record of transactions filed by Hillan Kenneth J., 董事. Insider active across 2 companies, notably 23andMe Holding Co.. Aggregated, 12 disclosures have been recorded. Split: 0 buy · 1 sell. Total volume traded: €32k. Activity tracked since 9 February 2022. The latest transaction was filed on 12 June 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 条申报中的 12 条
Hillan Kenneth J. is Chief Therapeutics Officer at 23andMe Holding Co. and Director at Sangamo Therapeutics, INC. He has 12 filings in total, and across the 12 sampled recent filings between 2022-02-11 and 2025-06-16, sales total EUR 31960 and the most common transaction nature is Attribution.